Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Bauknecht

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2010
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancerA Schneeweiss, F Marmé, A Ruiz, et al.
Seminars in Oncology|February 1, 1997
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trialH G Meerpohl, A du Bois, H J Luck, et al.
Seminars in Oncology|December 1, 1995
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancerH G Meerpohl, A du Bois, H Kühnle, et al.
Oncology|March 13, 2001
Evaluation of methods to detect p53 mutations in ovarian cancerI Meinhold-Heerlein, E Ninci, H Ikenberg, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II studyT Bauknecht, A Hefti, G Morack, et al.
Seminars in Oncology|January 14, 1998
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokineticsH Maier-Lenz, B Hauns, B Haering, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
The American Journal of Pathology|April 6, 2001
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancerI Meinhold-Heerlein, F Stenner-Liewen, H Liewen, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2010
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancerA Schneeweiss, F Marmé, A Ruiz, et al.
Seminars in Oncology|February 1, 1997
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trialH G Meerpohl, A du Bois, H J Luck, et al.
Seminars in Oncology|December 1, 1995
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancerH G Meerpohl, A du Bois, H Kühnle, et al.
Oncology|March 13, 2001
Evaluation of methods to detect p53 mutations in ovarian cancerI Meinhold-Heerlein, E Ninci, H Ikenberg, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II studyT Bauknecht, A Hefti, G Morack, et al.
Seminars in Oncology|January 14, 1998
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokineticsH Maier-Lenz, B Hauns, B Haering, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
The American Journal of Pathology|April 6, 2001
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancerI Meinhold-Heerlein, F Stenner-Liewen, H Liewen, et al.
Pageof 10